Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 6Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Leukemia, B-Cell 2Head and Neck Neoplasms 2Breast Neoplasms 2Vomiting 1Urinary Bladder Neoplasms 1Tracheal Diseases 1TP53 Y220C Mutation 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Nausea 1Myofibroma 1Mesothelioma 1

Interventions

Cyclophosphamide 17blinatumomab 16fludarabine 13Vincristine 11Cytarabine 10tisagenlecleucel 8pegaspargase 8nilotinib 8Methotrexate 8Inotuzumab Ozogamicin 8Clofarabine 8venetoclax 7Dexamethasone 7asparaginase erwinia chrysanthemi recombinant 6Dasatinib 6Azacitidine 5AP 1903 reagent 5aflibercept 4Mercaptopurine 4Imatinib Mesylate 4Filgrastim 4Etoposide 4Drug Therapy 4Daunorubicin 4ponatinib 3Sensitivity and Specificity 3Mitoxantrone 3Immunotherapy, Adoptive 3Granulocyte Colony-Stimulating Factor 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Tablets × Clear all
NCT01697020 2013-12-02

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Nova Laboratories Limited

Phase 1 Completed
70 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡